TCH346

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Amyotrophic Lateral Sclerosis

Conditions

Amyotrophic Lateral Sclerosis

Trial Timeline

Nov 1, 2004 → Feb 1, 2005

NCT ID

NCT00230074

About TCH346

TCH346 is a phase 2 stage product being developed by Novartis for Amyotrophic Lateral Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00230074. Target conditions include Amyotrophic Lateral Sclerosis.

What happened to similar drugs?

2 of 18 similar drugs in Amyotrophic Lateral Sclerosis were approved

Approved (2) Terminated (4) Active (12)

✅RiluzoleSanofiApproved

✅TofersenBiogenApproved

🔄methylcobalamin + saline solutionEisaiPhase 3

🔄Olesoxime + Placebo Comparator + RiluzoleRochePhase 3

🔄Tofersen + PlaceboBiogenPhase 3

❌DexpramipexoleBiogenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00230074	Phase 2	Completed	Nov 1, 2004	Feb 1, 2005	Amyotrophic Lateral Sclerosis
NCT00072709	Phase 2	Completed	Sep 1, 2003	Dec 1, 2004	Amyotrophic Lateral Sclerosis
NCT00036413	Phase 2	Completed	Jan 1, 2002	Oct 1, 2002	Amyotrophic Lateral Sclerosis

Competing Products

20 competing products in Amyotrophic Lateral Sclerosis

See all competitors

Product	Company	Stage	Hype Score
AL001 + Placebo	Alector	Phase 2	17
89Zr-DFO-AP-101	Eli Lilly	Phase 1	33
Reldesemtiv + Placebo	Astellas Pharma	Phase 2	35
Perampanel + Placebo Oral Tablet	Eisai	Pre-clinical	18
E0302 (mecobalamin)	Eisai	Phase 2/3	38
E0302 (mecobalamin) + E0302 (mecobalamin) + Placebo	Eisai	Phase 2/3	38
methylcobalamin + saline solution	Eisai	Phase 3	40
ONO-2506PO	Ono Pharmaceutical	Phase 2	35
ONO-2506PO + ONO-2506PO	Ono Pharmaceutical	Phase 2	35
ZYIL1 capsules 25 mg and 50 mg Placebo + ZYIL1 capsules 50 mg and 25 mg Placebo + ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg + Matching placebo 25 mg and Matching placebo 50 mg	Zydus Lifesciences	Phase 2	35
LY4256984 + Placebo	Eli Lilly	Phase 1	36
TCH346	Novartis	Phase 2	35
VHB937	Novartis	Phase 2	39
TCH346	Novartis	Phase 2	35
BLZ945	Novartis	Phase 2	27
TRO19622	Roche	Phase 2/3	38
Olesoxime + Placebo Comparator + Riluzole	Roche	Phase 3	40
Bosutinib (Phase 1 part) + Bosutinib (Phase 2 part)	Pfizer	Phase 1/2	28
Celecoxib + Creatine + Minocycline	Pfizer	Phase 2	35
DNL747 + Placebo	Sanofi	Phase 1	21